8 Questions to Ask Your Dermatologist Before Starting Systemic Treatment for Moderate to Severe Eczema

Patients managing moderate to severe atopic dermatitis face high-stakes clinical choices as they weigh systemic treatments against long-term safety and daily quality of life.

While the standard of care for eczema often begins with topical therapies and gentle skin care, more persistent cases necessitate systemic intervention. This transition requires clinicians to look beyond the skin, evaluating a patient’s age, treatment history, and the specific ways the condition disrupts sleep, daily function, and long-term milestones such as pregnancy or breastfeeding.

“A patient’s health history is a critical part of the decision for any medication,” said Steven Daveluy, a professor and program director of the dermatology residency program at Wayne State University’s School of Medicine.

The choice of medication often brings the complexities of FDA-mandated black box warnings into the consultation room. These warnings, which flag potential risks for serious infections, cancer, cardiovascular events, blood clots, and death, stem from studies on tofacitinib in rheumatoid arthritis patients aged 50 and older with existing cardiovascular risk factors.

“The goal is not to dismiss the warnings, but to interpret them thoughtfully and put them into context,” said Peter Lio, a clinical assistant professor of dermatology and pediatrics at Northwestern University’s Feinberg School of Medicine.

Physicians also warn that systemic relief is rarely immediate. Because these treatments work by modulating the immune system, patients must manage expectations regarding the timeline for skin healing.

“I like to remind patients that their disease did not come on overnight,” said Dawn Davis, a professor of dermatology and pediatrics at Mayo Clinic.

The treatment journey is further complicated by potential side effects—ranging from acne and headaches with JAK inhibitors to conjunctivitis linked to certain biologics—and the administrative hurdles of insurance coverage. Many insurers mandate step therapy, requiring patients to trial lower-cost options before accessing newer systemic drugs. When these barriers arise, clinics often provide support through appeals or financial aid programs.

“The most effective treatment on paper isn’t helpful if a patient cannot afford to take it,” Daveluy said.

For those currently on treatment, Davis emphasized that certain red-flag symptoms, such as chest discomfort, shortness of breath, or coughing up blood, necessitate immediate emergency medical attention, at which point the patient must disclose their current medication regimen. Patients seeking further guidance can consult resources provided by the American Academy of Dermatology Association and the National Eczema Association.

Photo of author

Health Desk

Health Desk at Archyde.

Last Danish Hunter-Gatherer Ate Farmer-Grown Food, Isotopes Show

Guardian: New Covent Garden Spot Cassette a ‘Clandestine Foodie Paradise’